Literature DB >> 29501519

A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.

Katherine L Tuttle1, Kathleen M Buchheit2, Tanya M Laidlaw2, Katherine N Cahill2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29501519      PMCID： PMC5997393          DOI： 10.1016/j.jaip.2018.01.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  11 in total

1.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

Authors:  Philippe Gevaert; Nicholas Van Bruaene; Tom Cattaert; Kristel Van Steen; Thibaut Van Zele; Frederic Acke; Natalie De Ruyck; Katrien Blomme; Ana R Sousa; Richard P Marshall; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2011-09-28       Impact factor: 10.793

2.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

3.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  Evidence for distinct histologic profile of nasal polyps with and without eosinophilia.

Authors:  Spencer C Payne; S Brandon Early; Phillip Huyett; Joseph K Han; Larry Borish; John W Steinke
Journal:  Laryngoscope       Date:  2011-09-06       Impact factor: 3.325

5.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

6.  The minimally important difference of the Asthma Control Test.

Authors:  Michael Schatz; Mark Kosinski; Aaron S Yarlas; Jennifer Hanlon; Maria E Watson; Priti Jhingran
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

7.  Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis.

Authors:  P Gevaert; C Bachert; G Holtappels; C P Novo; J Van der Heyden; L Fransen; S Depraetere; H Walter; P van Cauwenberge; J Tavernier
Journal:  Allergy       Date:  2003-05       Impact factor: 13.146

8.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

9.  Psychometric validity of the 22-item Sinonasal Outcome Test.

Authors:  C Hopkins; S Gillett; R Slack; V J Lund; J P Browne
Journal:  Clin Otolaryngol       Date:  2009-10       Impact factor: 2.597

10.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.

Authors:  Claus Bachert; Ana R Sousa; Valerie J Lund; Glenis K Scadding; Philippe Gevaert; Shuaib Nasser; Stephen R Durham; Marjolein E Cornet; Harsha H Kariyawasam; Jane Gilbert; Daren Austin; Aoife C Maxwell; Richard P Marshall; Wytske J Fokkens
Journal:  J Allergy Clin Immunol       Date:  2017-07-04       Impact factor: 10.793
View more
  19 in total

1.  Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.

Authors:  Ryan C Eid; Eden Wudneh; Soombal Zahid; Katherine Cahill; Elina Jerschow
Journal:  Ann Allergy Asthma Immunol       Date:  2019-10-09       Impact factor: 6.347

2.  Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.

Authors:  Auddie M Sweis; Tran B Locke; Kevin I Ig-Izevbekhai; Theodore C Lin; Ankur Kumar; Jennifer E Douglas; Andrew M Corr; Alyssa M Civantos; Siddhant H Tripathi; David W Kennedy; Michael A Kohanski; James N Palmer; Nithin D Adappa; John V Bosso
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 3.  Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.

Authors:  Elissa M Abrams; Allan B Becker; Stanley J Szefler
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2018-09-17       Impact factor: 1.349

4.  IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

Review 5.  NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.

Authors:  Tanya M Laidlaw; Joshua M Levy
Journal:  Curr Allergy Asthma Rep       Date:  2020-03-14       Impact factor: 4.806

Review 6.  Biologics in chronic rhinosinusitis with nasal polyposis.

Authors:  Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2019-12-09       Impact factor: 6.347

Review 7.  Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Kathryn E Hulse
Journal:  Ann Allergy Asthma Immunol       Date:  2020-10-13       Impact factor: 6.347

Review 8.  Approach to Eosinophilia Presenting With Pulmonary Symptoms.

Authors:  Chen E Rosenberg; Paneez Khoury
Journal:  Chest       Date:  2020-09-28       Impact factor: 9.410

9.  Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2021-06-16       Impact factor: 14.290

Review 10.  Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

Authors:  Ryan Eid; Carol H Yan; Whitney Stevens; Taylor A Doherty; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2021-08       Impact factor: 14.290
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.